Skip to main content
SABR
NASDAQ Technology

Sabre and Constellation Software Reach Governance Agreement, Terminating Poison Pill and Appointing New Director

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Travel & Leisure Stocks · Consumer
Sentiment info
Neutral
Importance info
9
Price
$1.7
Mkt Cap
$640.167M
52W Low
$0.81
52W High
$4.22
52W Position info
110% above low
Off High info
60% below high
Rel. Volume info
2.5× avg
Market data snapshot near publication time

SABR has more than doubled off its 52-week low of $0.81 on elevated volume (2.5× avg).

Summary

Sabre Corporation and major shareholder Constellation Software Inc. have entered into a strategic governance agreement, leading to the appointment of a Constellation representative to Sabre's board and the termination of the recently adopted shareholder rights plan.


Key Events · Corporate Governance and Compliance · SABR

  • Strategic Governance Agreement Reached

    Sabre Corporation and Constellation Software Inc. entered into a Strategic Governance Agreement to resolve governance matters.

  • Board Appointment

    Damian McKay, CEO of Vela Software Group (a Constellation division), will be appointed to Sabre's Board of Directors.

  • Poison Pill Terminated

    The shareholder rights plan, adopted on March 2, 2026, is being terminated, accelerating its expiration to March 6, 2026.

  • Standstill Agreement

    Constellation Software agrees to a standstill, limiting its beneficial ownership to 15% of Sabre's common stock and committing to vote with the board on most proposals.


Analysis · SABR · Technology

This 8-K filing signals a significant de-escalation of potential conflict between Sabre Corporation and its major shareholder, Constellation Software Inc. Just days after Sabre implemented a shareholder rights plan (poison pill) with a 15% trigger on March 2, 2026, this agreement resolves the immediate tension. Constellation, which recently increased its stake by over $12.3 million to approximately 12.7%, gains a board seat, providing it with direct influence over the company's strategic direction. In return, Constellation agrees to a standstill, limiting its aggregate beneficial ownership to 15% and committing to vote with the board on most matters. The termination of the poison pill, enacted on March 2, 2026, is a critical development, indicating that the company and Constellation have found a mutually agreeable path forward, avoiding a potentially costly and disruptive proxy fight. This outcome provides near-term stability and clarity regarding Sabre's governance structure.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SABR was trading at $1.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $640.2M. The 52-week trading range was $0.81 to $4.22. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SABR - Latest Insights

SABR
Nov 05, 2026, 8:03 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.88
Real-time Price: $1.84 info
Change: -$0.040 (-2%) info
Market Cap: $751.047M info
SABR
Nov 05, 2026, 7:43 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $1.91
Real-time Price: $1.84 info
Change: -$0.070 (-4%) info
Market Cap: $751.047M info
SABR
Nov 05, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $1.84 info
Change: +$0.0479 (+3%) info
Market Cap: $751.047M info
SABR
Sep 28, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.10
Real-time Price: $1.84 info
Change: -$0.260 (-12%) info
Market Cap: $751.047M info
SABR
Sep 25, 2026, 6:55 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $2.18
Real-time Price: $1.84 info
Change: -$0.340 (-16%) info
Market Cap: $751.047M info